Search
Search
About
Log in
Join
Experiences with
Elbasvir / Grazoprevir
Posts
Communities
14 public posts
Filter results
Zepatier highly effective for inducing SVR in HCV patients with prior treatment failure
"Overall, 92.4% of patients achieved SVR12 with 12 weeks of
elbasvir
/
grazoprevir
, and 94.2% of patients achieved SVR12 with 12 weeks of
elbasvir
/
grazoprevir
plus ribavirin." http://bit.ly/2jA3VFm
"Overall, 92.4% of patients achieved SVR12 with 12 weeks of
elbasvir
/
grazoprevir
, and 94.2% of patients achieved SVR12 with 12 weeks of
elbasvir
/
grazoprevir
plus ribavirin." http://bit.ly/2jA3VFm
HFIAdmin
in
HFI Connect - Hepatitis
8 years ago
Zepatier highly effective for inducing SVR in HCV patients with prior treatment failure
"Overall, 92.4% of patients achieved SVR12 with 12 weeks of
elbasvir
/
grazoprevir
, and 94.2% of patients achieved SVR12 with 12 weeks of
elbasvir
/
grazoprevir
plus ribavirin." http://bit.ly/2jA3VFm
"Overall, 92.4% of patients achieved SVR12 with 12 weeks of
elbasvir
/
grazoprevir
, and 94.2% of patients achieved SVR12 with 12 weeks of
elbasvir
/
grazoprevir
plus ribavirin." http://bit.ly/2jA3VFm
HFIAdmin
in
Hepatitis C Support
8 years ago
INHSU 2016: Risk of Reinfection Is a Concern After Successful Hepatitis C Treatment
People on opiate agonist substitution therapy can be successfully treated with
grazoprevir
/
elbasvir
(Zepatier) -- achieving cure rates similar to those of the population as a whole -- but some people are reinfected with hepatitis C virus after being cured, suggesting that a ... http://bit.ly/2cJwETM
People on opiate agonist substitution therapy can be successfully treated with
grazoprevir
/
elbasvir
(Zepatier) -- achieving cure rates similar to those of the population as a whole -- but some people are reinfected with hepatitis C virus after being cured, suggesting that a ... http://bit.ly/2cJwETM
HFIAdmin
in
HFI Connect - Hepatitis
8 years ago
Want to take advantage of all our features? Just log in!
Log in
or
Join
FDA OKs Merck’s Zepatier (Grazoprevir/Elbasvir) to Treat Hep C
https://www.hepmag.com/article/fda-oks-mercks-zepatier-grazoprevirelbasvir-treat-hepatitis-c?utm_source=phplist69&utm_medium=email&utm_content=HTML&utm_campaign=FDA+OKs+Zepatier+%28Grazoprevir%2FElbasvir%29+to+Treat+Hep+C+
https://www.hepmag.com/article/fda-oks-mercks-zepatier-grazoprevirelbasvir-treat-hepatitis-c?utm_source=phplist69&utm_medium=email&utm_content=HTML&utm_campaign=FDA+OKs+Zepatier+%28Grazoprevir%2FElbasvir%29+to+Treat+Hep+C+
HFIAdmin
in
HFI Connect - Hepatitis
9 years ago
The Combination of Elbasvir and Grazoprevir ± RBV Is HighlyEffective for the Treatment of GT1a-Infected Patients
http://www.natap.org/2015/AASLD/AASLD_18.htm
http://www.natap.org/2015/AASLD/AASLD_18.htm
kcohen
in
HFI Connect - Hepatitis
9 years ago
C-EDGE: Grazoprevir/elbasvir benefits HIV/HCV coinfected patients
http://www.healio.com/hepatology/hepatitis-c/news/online/%7Bb9f3c1c8-ee0a-4a84-a91f-7656272ee5d8%7D/c-edge-grazoprevirelbasvir-benefits-hivhcv-coinfected-patients?utm_source=maestro&utm_medium=email&utm_campaign=hepatology%20news
http://www.healio.com/hepatology/hepatitis-c/news/online/%7Bb9f3c1c8-ee0a-4a84-a91f-7656272ee5d8%7D/c-edge-grazoprevirelbasvir-benefits-hivhcv-coinfected-patients?utm_source=maestro&utm_medium=email&utm_campaign=hepatology%20news
kcohen
in
HFI Connect - Hepatitis
9 years ago
AASLD 2015: Grazoprevir/ Elbasvir Shows High Cure Rate for People Who Inject Drugs | Experimental HCV Drugs
http://hivandhepatitis.org/hcv-treatment/experimental-hcv-drugs/5474-aasld-2015-grazoprevirelbasvir-shows-high-cure-rate-for-people-who-inject-drugs
http://hivandhepatitis.org/hcv-treatment/experimental-hcv-drugs/5474-aasld-2015-grazoprevirelbasvir-shows-high-cure-rate-for-people-who-inject-drugs
kcohen
in
HFI Connect - Hepatitis
9 years ago
HCV New Drug Treatment: Merck to Present New Data on HCV Treatment Elbasvir/ Grazoprevir at the Liver Meeting 2015
http://hepatitiscnewdrugs.blogspot.com/2015/10/merck-to-present-new-data-on-hcv.html
http://hepatitiscnewdrugs.blogspot.com/2015/10/merck-to-present-new-data-on-hcv.html
kcohen
in
HFI Connect - Hepatitis
9 years ago
Eyeing big returns, drugmakers ready new hepatitis-C drug launches
Earlier this week the company said that the FDA had accepted an NDA for
grazoprevir
/
elbasvir
, an investigational daily single-tablet combination therapy for hepatitis C. The regulator is expected to decide on the drug by Jan. 28.
Earlier this week the company said that the FDA had accepted an NDA for
grazoprevir
/
elbasvir
, an investigational daily single-tablet combination therapy for hepatitis C. The regulator is expected to decide on the drug by Jan. 28.
kcohen
in
HFI Connect - Hepatitis
9 years ago
Merck Seeks FDA Approval of Hep C Tablet Grazoprevir/Elbasvir
Merck’s application is based in part on data from the C-EDGE, C-SURFER and C-SALVAGE clinical trials, which studied
grazoprevir
/
elbasvir
with and without ribavirin.
Merck’s application is based in part on data from the C-EDGE, C-SURFER and C-SALVAGE clinical trials, which studied
grazoprevir
/
elbasvir
with and without ribavirin.
kuzoigwe
in
HFI Connect - Hepatitis
9 years ago
Merck Seeks FDA Approval of Hep C Tablet Grazoprevir/Elbasvir
Merck’s application is based in part on data from the C-EDGE, C-SURFER and C-SALVAGE clinical trials, which studied
grazoprevir
/
elbasvir
with and without ribavirin.
Merck’s application is based in part on data from the C-EDGE, C-SURFER and C-SALVAGE clinical trials, which studied
grazoprevir
/
elbasvir
with and without ribavirin.
kuzoigwe
in
HFI Connect - Hepatitis
9 years ago
MSD Announces Results from Phase 2/3 Study of Investigational Chronic Hepatitis C Therapy
Grazoprevir
/
Elbasvir
in Patients with Advanced Chronic Kidney Disease C-SURFER Trial is First to Investigate an All-Oral Ribavirin-Free Hepatitis C Treatment Regimen in Treatment-Naïve and Treatment-Experienced Patients with Advanced Chronic Kidney Disease Infected with Hepatitis C Virus Genotype 1
Grazoprevir
/
Elbasvir
in Patients with Advanced Chronic Kidney Disease C-SURFER Trial is First to Investigate an All-Oral Ribavirin-Free Hepatitis C Treatment Regimen in Treatment-Naïve and Treatment-Experienced Patients with Advanced Chronic Kidney Disease Infected with Hepatitis C Virus Genotype 1
kuzoigwe
in
HFI Connect - Hepatitis
9 years ago
Merck Announces Presentation of Phase 2 Clinical Trial
Merck Announces Presentation of Phase 2 Clinical Trial Results of Investigational Chronic Hepatitis C Therapy
Grazoprevir
/
Elbasvir
at the International Liver Congress™ 2015 http://hepatitiscresearchandnewsupdates.blogspot.com/2015/04/merck-announces-presentation-of-phase-2.html
Merck Announces Presentation of Phase 2 Clinical Trial Results of Investigational Chronic Hepatitis C Therapy
Grazoprevir
/
Elbasvir
at the International Liver Congress™ 2015 http://hepatitiscresearchandnewsupdates.blogspot.com/2015/04/merck-announces-presentation-of-phase-2.html
kuzoigwe
in
HFI Connect - Hepatitis
9 years ago
Merck’s Hep C Meds Work Well in Treatment-Experienced People
Twelve weeks of Merck’s
grazoprevir
and
elbasvir
, plus ribavirin, cured nearly all treatment-experienced people with genotype 1 of hepatitis C virus (HCV) in a small trial, including those with cirrhosis.
Twelve weeks of Merck’s
grazoprevir
and
elbasvir
, plus ribavirin, cured nearly all treatment-experienced people with genotype 1 of hepatitis C virus (HCV) in a small trial, including those with cirrhosis.
kuzoigwe
in
HFI Connect - Hepatitis
9 years ago
Filter results
Clear filters
Posted in
All communities
HFI Connect - Hepatitis
13 results
Hepatitis C Support
1 result
Sort by
Most Relevant
Newest